The 5-HT7 receptor and disorders of the nervous system: an overview

Psychopharmacology (Berl). Author manuscript; available in PMC Oct 1, 2010.
Published in final edited form as:
Psychopharmacology (Berl). Oct 2009; 206(3): 345–354.
Published online Aug 1, 2009. doi: 10.1007/s00213-009-1626-0
PMCID: PMC2841472
NIHMSID: NIHMS145747
The 5-HT7 receptor and disorders of the nervous system: an overview
Peter B. Hedlund
Author information ► Copyright and License information ►
The publisher's final edited version of this article is available at Psychopharmacology (Berl)
See other articles in PMC that cite the published article.
Go to:
Abstract
Rationale

The 5-HT7 receptor is a more recently discovered G-protein-coupled receptor for serotonin. The functions and possible clinical relevance of this receptor are not yet fully understood.

Objective

The present paper reviews to what extent the use of animal models of human psychiatric and neurological disorders have implicated the 5-HT7 receptor in such disorders. The studies have used a combination of pharmacological and genetic tools targeting the receptor to evaluate effects on behavior.

Results

Models of anxiety and schizophrenia have yielded mixed results with no clear role for the 5-HT7 receptor described in these disorders. Some data are available for epilepsy, migraine, and pain but it is still very early to draw any definitive conclusions. There is a considerable amount of evidence supporting a role for the 5-HT7 receptor in depression. Both blockade and inactivation of the receptor have resulted in an antidepressant-like profile in models of depression. Supporting evidence has also been obtained in sleep studies. Especially interesting are the augmented effects achieved by combining antidepressants and 5-HT7 receptor antagonists. The antidepressant effect of amisulpride has been shown to most likely be mediated by the 5-HT7 receptor.

Conclusions

The use of pharmacological and genetic tools in preclinical animal models strongly supports a role for the 5-HT7 receptor in depression. Indirect evidence exists showing that 5-HT7 receptor antagonism is clinically useful in the treatment of depression. Available data also indicate a possible involvement of the 5-HT7 receptor in anxiety, epilepsy, pain, and schizophrenia.

Keywords: anxiety, depression, epilepsy, migraine, pain, schizophrenia, sleep

which role does thins one have for schizos?

dueler wrote:which role does thins one have for schizos?

Mixed, blocking it has an anti-depressant and anti-anxiety effect, activating it seems to have a slight anti-psychotic effect in some circumstances...and may also boost testosterone.

Bumping this, may be relevant for Epileptics as well!!

Neurosci Lett. 2004 Apr 8;359(1-2):45-8.
Selective 5-HT1A and 5-HT7 antagonists decrease epileptic activity in the WAG/Rij rat model of absence epilepsy.
Graf M1, Jakus R, Kantor S, Levay G, Bagdy G.
Author information
Abstract
Recent studies have provided evidence that activation of 5-HT1A receptors increases epileptic activity in the WAG/Rij rat model of absence epilepsy, and additional data have suggested the involvement of 5-HT7 receptors as well. Therefore, we have tested the effects of the selective 5-HT1A receptor antagonist WAY-100635 and the selective 5-HT7 receptor antagonist SB-258719 on spontaneous epileptic activity. In general, both compounds reduced epileptic activity compared to vehicle. Significant decreases were found in the number of paroxysms and the cumulative and average duration of spike-wave discharges (SWDs), although the time courses of these effects induced by the two compounds were clearly different. These results provide evidence that activation of 5-HT1A and 5-HT7 receptors plays a significant role in regulating SWD activity in this animal model of absence epilepsy.
PMID: 15050708 [PubMed - indexed for MEDLINE]

~

Seems like all the new antidepressants block this 5-HT7-receptor; Trintellix (Vortioxetine), Brexpriprazole (Rexulti) and Latuda (Lurasidone).